scholarly journals A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia

2016 ◽  
Vol 176 (2) ◽  
pp. 241-247 ◽  
Author(s):  
Amer M. Zeidan ◽  
B. Douglas Smith ◽  
Hetty E. Carraway ◽  
Ivana Gojo ◽  
Amy DeZern ◽  
...  
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Myelodysplastic Syndromes ◽  
High Dose ◽  
Phase 2 ◽  
Phase 2 Trial ◽  
Acute Myeloid

scholarly journals Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial

2019 ◽  
Vol 6 (1) ◽  
pp. e29-e37 ◽  
Author(s):  
Nicholas J Short ◽  
Hagop M Kantarjian ◽  
Sanam Loghavi ◽  
Xuelin Huang ◽  
Wei Qiao ◽  
...  
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Older Patients ◽  
Phase 2 ◽  
Newly Diagnosed ◽  
Phase 2 Trial ◽  
Acute Myeloid

Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial

2020 ◽  
Vol 7 (2) ◽  
pp. e122-e133 ◽  
Author(s):  
Andrew M Brunner ◽  
Traci M Blonquist ◽  
Daniel J DeAngelo ◽  
Malgorzata McMasters ◽  
Geoffrey Fell ◽  
...  
Keyword(s):  
High Risk ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Induction Chemotherapy ◽  
Phase 2 ◽  
Phase 2 Trial ◽  
Acute Myeloid

scholarly journals Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial

2018 ◽  
Vol 19 (7) ◽  
pp. 889-903 ◽  
Author(s):  
Jorge Cortes ◽  
Alexander E Perl ◽  
Hartmut Döhner ◽  
Hagop Kantarjian ◽  
Giovanni Martinelli ◽  
...  
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Phase 2 ◽  
Open Label ◽  
Phase 2 Trial ◽  
Flt3 Inhibitor ◽  
Acute Myeloid
Sign in / Sign up

Export Citation Format

Share Document